Delivery Order SPE2DB24D1205-SPE2DB25FCZMB
- Not listed
- The Defense Logistics Agency awarded a $10,662.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tagrisso 80 mg tablets (30-count units) on August 15, 2025, with completion targeted for September 8, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $58,164.68 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 24, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, and this order supports the...
- The Defense Logistics Agency awarded a $31,987.71 delivery order to AmerisourceBergen Drug Corp for 30-tablet units of Tagrisso 80 mg tablets under a firm fixed price contract. This delivery order, issued on September 25, 2025, with an ultimate completion date of October 17, 2025, represents a non-competitive set-aside award to the pharmaceutical distributor. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a $42,650.28 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 7, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in the treatment of certain lung cancers, and this award...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units). This firm fixed-price, non-set-aside contract was awarded on August 20, 2025, with an ultimate completion date of September 11, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, and this delivery order represents one...
- The Defense Logistics Agency awarded a $21,325.14 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price contract with an ultimate completion date of October 9, 2025. The award represents a non-set-aside, competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a $31,987.71 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by October 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, consistent...
- The Defense Logistics Agency awarded a $10,662.57 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Tagrisso 80 mg tablets (30-unit package). This contract represents a competitive, firm fixed-price procurement with no set-aside designation and a completion date of September 10, 2025. The award is executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Tagrisso 80 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $10,662.57. The order is scheduled for completion by September 2, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a contract ceiling value of $10,662.57. This firm fixed-price delivery order, which is expected to be completed by October 3, 2025, represents a non-set-aside competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZMBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in cancer treatment, reflecting the breadth of pharmaceutical products that DLA procures to support military healthcare systems. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through this comprehensive global pharmaceutical support vehicle. The IDC enables the company to supply a wide range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military medical operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 8/12/25 |